Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis
Allergol. immunopatol
; 43(3): 298-303, mayo-jun. 2015. ilus, tab
Article
in En
| IBECS
| ID: ibc-136338
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
BACKGROUND: Infections by respiratory syncytial virus (RSV) are more severe in patients with cystic fibrosis (CF), and many CF units use palivizumab as prophylaxis; however, information about palivizumab efficacy in CF patients is almost lacking. METHODS: A literature search up to December 2012 on the morbidity of RSV bronchiolitis in CF patients and on the safety and efficacy of palivizumab in those patients was performed. A random-effects meta-analysis was conducted for those studies meeting pre-specified search criteria. Historical controls were allowed. RESULTS: The number of patients who received palivizumab was 354 and the hospital admission rate was 0.018 (95% CI 0.0077-0.048). The corresponding number in the non-treated groups was 463 patients with an admission rate of 0.126 (95% CI 0.086-0.182) (Q = 13.9; p < 0.001). CONCLUSION: Palivizumab may have a role in the prevention of severe lower airway infection by RSV in CF patients
RESUMEN
No disponible
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Bronchiolitis
/
Respiratory Syncytial Virus Infections
/
Antibiotic Prophylaxis
/
Antibodies, Monoclonal
Type of study:
Observational_studies
/
Systematic_reviews
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Allergol. immunopatol
Year:
2015
Document type:
Article